← Back to Analyst Consensus 
INO Buy
INOVIO PHARMACEUTICALS, INC.
Current Price —
Implied Upside —
Analysts 7
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 13, 2026 | Jefferies | upgrade | Hold → Buy | — | 52% |
| Aug 3, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Jun 1, 2026 | HC Wainwright & Co. | maintain | Neutral → Neutral | — | 44% |
| Nov 14, 2025 | Piper Sandler | reiterate | Overweight → Overweight | $6 | 54% |
| Aug 14, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $3 | 44% |
| Jul 9, 2025 | Piper Sandler | initiate | — → Overweight | $5 | 54% |
| May 14, 2025 | RBC Capital | reiterate | Sector Perform → Sector Perform | $5 | 55% |
| May 14, 2025 | Oppenheimer | maintain | Outperform → Outperform | $13 | 52% |
| Mar 19, 2025 | RBC Capital | maintain | Sector Perform → Sector Perform | $5 | 55% |
| Mar 19, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $3 | 44% |
| Jan 13, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $3 | 44% |
| Jan 10, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $18 | 53% |
| Nov 18, 2024 | HC Wainwright & Co. | maintain | Neutral → Neutral | $5 | 44% |
| Nov 18, 2024 | Oppenheimer | maintain | Outperform → Outperform | $15 | 52% |
| Nov 15, 2024 | RBC Capital | maintain | Sector Perform → Sector Perform | $6 | 55% |
| Aug 12, 2024 | Oppenheimer | maintain | Outperform → Outperform | $33 | 52% |
| Aug 9, 2024 | RBC Capital | maintain | Sector Perform → Sector Perform | $8 | 55% |
| Jul 15, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $15 | 44% |
| May 14, 2024 | Stephens & Co. | initiate | — → Overweight | $20 | 54% |
| Mar 8, 2024 | Oppenheimer | maintain | Outperform → Outperform | $40 | 52% |
| Mar 7, 2024 | RBC Capital | reiterate | Sector Perform → Sector Perform | $11 | 55% |
| Jan 25, 2024 | Oppenheimer | upgrade | Perform → Outperform | $4 | 52% |
Price Target Trend
Apr 26, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
+1y —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days